Skip to main content

Table 1 Summary of patient characteristics (mean ± SE)

From: ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion

  RA
(n = 23)
OA
(n = 16)
Healthy control
(n = 7)
Age 56.6 ± 3.4 64.2 ± 6.2 46 ± 4.6
Female, n (%) 17 (74) 13 (81) 3 (43)
Methotrexate dose (mg/week) 7.9 ± 1.2   
Glucocorticoid dose (mg/day) 1.33 ± 0.5   
DAS28 (ESR) 4.81 ± 0.3   
Duration (years) 5.2 ± 1.0   
RF positive (%) 78.3   
ACPA positive (%) 65.2   
Stage (I/II/III/IV) (7/8/4/4)   
Number of previous biologics 1.0 ± 0.3   
  1. ACPA anti-citrullinated protein antibodies, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate, ICAM-1 intercellular adhesion molecule 1, RF rheumatoid factor